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Membranous nephropathy is a common cause of nephrotic
syndrome in adults. Although some patients with
membranous nephropathy achieve a spontaneous remission,
renal function continues to deteriorate in others. We
conducted a prospective randomized trial evaluating
monotherapy with tacrolimus to achieve complete or partial
remission in patients with biopsy-proven membranous
nephropathy. Twenty-five patients received tacrolimus
(0.05 mg/kg/day) over 12 months with a 6-month taper,
whereas 23 patients were in the control group. The
probability of remission in the treatment group was 58, 82,
and 94% after 6, 12, and 18 months but only 10, 24, and 35%,
respectively in the control group. The decrease in proteinuria
was significantly greater in the treatment group. Notably, six
patients in the control group and only one in the treatment
group reached the secondary end point of a 50% increase in
their serum creatinine. No patient in the tacrolimus group
showed a relapse during the taper period. Nephrotic
syndrome reappeared in almost half of the patients who
were in remission by the 18th month after tacrolimus
withdrawal. We conclude that tacrolimus is a very useful
therapeutic option for patients with membranous
nephropathy and preserved renal function. The majority of
patients experienced remission with a significant reduction in
the risk for deteriorating renal function.
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Membranous nephropathy (MGN) is a frequent cause of
nephrotic syndrome in adults. Although the treatment of
MGN remains a much-debated issue, the number of
randomized controlled trials testing specific therapeutic
alternatives is scarce. Immunosuppressive therapy with
steroids and cytotoxics such as chlorambucil or cyclophos-
phamide has demonstrated a good efficacy in patients with
nephrotic syndrome and normal renal function in several
prospective trials.1–3 Nevertheless, serious adverse effects of
these aggressive therapeutic approaches are an important
concern, considering the advanced age of the majority of
MGN patients. On the other hand, a considerable percentage
of MGN patients achieve spontaneous remission during the
clinical course. On the basis of these caveats, some authors
restrict the use of steroid and cytotoxic combinations to those
patients with more unfavorable prognostic markers (particu-
larly, patients with massive nephrotic syndrome and deterio-
rating renal function).4,5 Other authors even recommend to
avoid any type of immunosuppressive approach given the
long-term good prognosis of most of the patients.6 However,
this radically conservative approach has also been criticized
because an important percentage of patients, ranging from 20
to 50%, develop progressive renal insufficiency.7–9
Another therapeutic approach that has been tested in
prospective randomized trial is cyclosporine. After some
nonrandomized studies showing a beneficial effect of this
drug on MGN,10 Cattran et al.11 demonstrated that
cyclosporin significantly improved renal outcome of patients
with MGN and progressive decline in renal function. In a
later prospective and multicenter trial performed in North
America,12 cyclosporin was tested in patients with MGN and
preserved renal function. Seventy-five percent of the treat-
ment group had a partial remission (PR) or complete
remission (CR), although the number of relapses after
cyclosporin withdrawal was high.
To evaluate the efficacy of tacrolimus, an anticalcineuri-
nic agent widely used as immunosuppressive therapy in
transplantation, we conducted a multicenter randomized
controlled trial with tacrolimus monotherapy in patients
with biopsy-proven MGN and preserved renal function,
and with persistent nephrotic syndrome for more than
9 months despite treatment with angiotensin-converting
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enzyme inhibitors (ACEI) or angiotensin receptor blockers
(ARB).
RESULTS
A total of 48 patients with biopsy-proven MGN and fulfilling
the trial criteria entry were randomly assigned to receive
tacrolimus treatment (treatment group, n¼ 25) or to a
control group (n¼ 23) (Figure 1). Demographic, histological,
and laboratory characteristics at baseline are expressed in
Table 1. Most patients in both groups were male and
displayed histological stage II on renal biopsy. There were no
differences in the number of patients that had been
previously treated with steroids alone or in combination
with cytotoxics. As shown in Table 1, diastolic blood pressure
(BP) was significantly higher in control group than in
tacrolimus group at baseline. Thereafter, however, there were
no more significant differences in both systolic and diastolic
BP between both groups during follow-up, as shown in
Figure 2. Table 2 summarizes the types and doses of ACEI
and ARB, as well as the number of patients that needed
statins and antihypertensive agents other than ACEI and ARB
during the study.
Primary end point
As shown in Figure 3, a significantly higher number of CR
and PR was observed in tacrolimus-treated patients since the
first 2 months of follow up. The percentages of remission in
tacrolimus group vs control group were 36 vs 9%,
respectively, by 2 months (Po0.04), 56 vs 13% by 6 months
(Po0.01), and 72 vs 22% by 12 months (Po0.001).
Significant differences between groups persisted along the
period of tacrolimus tapering (months 12–18). The percen-
tage of patients in remission was 76% in treated patients vs
30% in control group by 18 months (P¼ 0.003). Mean time
to PR or CR was 6.1 months (95% confidence interval (CI):
3.9–8.3) in tacrolimus group and 11.3 months (95% CI:
8.7–13.9) in control group (P¼ 0.003).
The probability of either PR or CR, estimated by
Kaplan–Meier method, was significantly higher in the
treatment group, as shown in Figure 4: 58 vs 10%, 82 vs
24%, and 94 vs 35%, after 6, 12, and 18 months, respectively
(Po0.00001 by log-rank test).
Patients who reached PR or CR, irrespective of treatment
group, were younger (41.7 years, 95% CI: 38.2–45.9, vs 53
years, 95% CI: 46.8–59.2) (P¼ 0.002), and had better
preserved renal function at baseline: serum creatinine (SCr)
0.95 mg/dl, (95% CI: 0.88–1.02) vs 1.16 mg/dl (95% CI:
1.05–1.27), and estimated glomerular filtration rate (eGFR)
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Figure 1 | Trial profile.
Table 1 | Demographic, histological and laboratory characteristics of patients at baseline
Control (n=23) Tacrolimus (n=25) P-value
Age 50.1712.2 43.7712.1 NS
Distribution of ages by tertiles (o40/40–50/450 years) 8/4/11 10/9/6 NS
Gender M/F 20/3 20/5 NS
Time since diagnosis (renal biopsy) (months) 45766 587100 NS
Glomerular stage at renal biopsy (I, II, III, and IV) 4/18/1/0 4/15/3/0 NS
Scr (mg/dl) 1.170.3 0.9870.2 NS
eGFR (ml/min/1.73 m2) 107763 104726 NS
Distribution of eGFR (490/60–89/50–59 ml/min/1.73 m2) 12/7/4 15/9/1 NS
Proteinuria (g/24 h) 8.475.4 7.273.3 NS
Distribution of proteinuria by tertiles (3.5–5 /5–9 /49 g/24 h) 8/5/10 6/11/8 NS
Serum albumin (g/dl) 2.970.8 2.770.8 NS
Systolic BP (mm Hg) 133.5723.5 123.8716.8 NS
Diastolic BP (mm Hg) 79.778.9 73.878.6 P=0.03
Previous treatment with steroids/steroids plus cytotoxics 5/4 6/4 NS
BP, blood pressure; eGFR, estimated glomerular filtration rate; F, female; M, male; NS, not significant; Scr, serum creatinine.
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Figure 2 | Evolution of systolic and diastolic BP during the study
(’, Control group and m, tacrolimus group).
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1.73 m2 (95 CI: % 69.7–96.5), respectively (P¼ 0.001). No
spontaneous remissions were observed among patients over
50 in the control group; by contrast four out of six (66%)
patients over 50 in the tacrolimus group achieved PR or CR
(Po0.02). By multivariate analysis, baseline eGFR (OR 1.06,
95% CI: 1.02–1.09, P¼ 0.004) and the treatment group (OR
16.1, 95% CI: 2.7–96.1, P¼ 0.002) were the only factors
statistically significantly correlated with the achievement of a
PR or CR.
No patients in the tacrolimus group showed nephrotic
syndrome relapse within the period of drug tapering, months
12–18. After tacrolimus withdrawal, nephrotic syndrome
reappeared in nine out of the 19 patients of tacrolimus group
(47%) who were on CR or PR by month 18 (Figure 3). Time
to nephrotic syndrome relapse after tacrolimus withdrawal
was 4.2 months (95% CI: 1.6–6.7).
Secondary end points
Six patients in the control group (26%) and one in the
tacrolimus group (4%) reached the secondary end point of a
50% SCr increase during the study (Po0.03) (Figure 5).
Time to reach renal insufficiency in the control group was 5.3
months (95% CI: 2.8–7.9). Mean age of these six patients was
significantly higher than those of the remaining 17 patients of
control group (60.8 years, 95% CI: 52.2–74.6 vs 45.9 years,
95% CI: 40.5–47.6, P¼ 0.008) and their baseline SCr was
higher (1.4 mg/dl, 95% CI: 1.16–1.6 mg/dl vs 1 mg/dl, 95%
CI: 0.94–1.05, P¼ 0.001). All of them showed massive
proteinuria since the onset of study, and when reaching the
secondary end point, proteinuria was 9.9 g/24 h (95% CI:
4.3–15.5). According to the study design, they were retired
from the study and most of them treated with tacrolimus or
with steroids and cytotoxics, according to the criteria of each
investigator. One patient died because of an ischemic stroke
shortly after being retired from the study, with progressing
renal insufficiency and persistent nephrotic syndrome.
The only patient treated with tacrolimus who developed
renal insufficiency was a 79-year-old male with baseline SCr
of 1.2 mg/dl, eGFR of 50 ml/min/1.73 m2 and proteinuria of
7.4 g/24 h. SCr started to increase by month 6 in spite of
tacrolimus dose reduction. By month 8, greater than 50%







Enalapril (20–40 mg/day) 6 4
Ramipril (5–20 mg/day) 0 3
Lisinopril (20–30 mg/day) 3 3
Total 9 10
ARB
Losartan (50–100 mg/day) 8 9
Candesartan (16 mg/day) 4 4
Irbersartan (150–300 mg/day) 2 1







ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
BB, b-blockers; CCB, calcium channel blockers.
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Figure 3 | Percentage of complete (grey) and partial (white)
remissions in the tacrolimus (T) and in the control (C) group.
Numbers within columns indicate the total number of patients in CR
or PR in both groups.
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Figure 4 | Probability of remission (either CR or PR) in
tacrolimus-treated group (solid line) and control group
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Figure 5 | Percentage of patients reaching the secondary end
point (a 50% SCr increase) during the study in tacrolimus-treated
group (T) and control group (C).
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SCr increase was observed, along with persistent nephrotic
syndrome, and tacrolimus was withdrawn according to
protocol, although no amelioration of renal function was
observed.
Proteinuria decreased significantly in both groups by
months 6, 12, and 18. In the treatment group, it decreased
from 7.3 g/24 h (95% CI: 5.4–9.4) to 1.6 g/24 h (95% CI:
0.8–3) (Po0.0001) by month 12 and to 1.9 g/24 h (95% CI:
0.5–3.8) by month 18 (Po0.0001); and in the control group,
from 8.4 g/24 h (95% CI 4.8–9.2) at baseline to 4.1 g/24 h
(95% CI: 1.8–5.9) by month 12 (Po0.001) and to 3.2 g/24 h
by month 18 (95% CI: 1.2–5.2) (Po0.005). The decrease in
proteinuria was significantly greater in the treated group
compared with control group at any time point, 6 months
(P¼ 0.002), 12 months (P¼ 0.045), and 18 months
(P¼ 0.048).
Tacrolimus treatment
Tacrolimus was slowly withdrawn between months 12 and 18
(Materials and Methods). Mean doses and blood levels of
tacrolimus are illustrated in Figure 6.
Adverse events
A list of the side effects observed in control and treated
groups is shown in Table 3. All of them were mild and
transitory. Tacrolimus was well tolerated and no patient
withdrew from the study owing to tacrolimus side effects.
Four patients in the tacrolimus group and two in control
group (P¼NS) developed mild glucose intolerance, which
was controlled by diet. Neither thrombotic events nor serious
infections were observed during the study. Two patients of
the treated group (personal decision because lack of response
after 6 months of treatment and a partial seizure in a patient
with history of epilepsy) and one of the control group (severe
edema six months after randomization and deafness
attributed to high-dose diuretics) withdrew from the study.
Five patients (three in the control group and two in the
treatment group) were lost to follow up between 3 and 18
months after randomization.
DISCUSSION
Our study is the first to show in a prospective and
randomized design that tacrolimus monotherapy is able to
modify significantly the outcome of patients with MGN,
inducing remission in a very considerable number of
patients. The probability of remission, estimated by Kaplan–-
Meier method, achieved 82% after 12 months of treatment
and 94% at the end of tacrolimus-withdrawal period (18
month) in comparison with 24 and 35%, respectively, in the
control group. These results confirm the deep therapeutical
influence of anticalcineurinic agents in MGN, previously
demonstrated by cyclosporin.11,12 As in the trials using
cyclosporin, most of tacrolimus-induced remissions were
partial. However, it is important to emphasize in this regard
that the achievement of remission, even partial, significantly
improves the prognosis of MGN on the long term.13
Another very important finding of our study was that
tacrolimus significantly reduced the risk of renal function
worsening. Studies about the natural history of non-treated
MGN have reported a considerable number of spontaneous
remissions (ranging between 20 and 40% of patients) and a
similar percentage of patients that exhibit an aggressive
clinical course, with progressively deteriorating renal func-
tion.6–9 Importantly, the appearance of renal function
worsening in these latter cases is always accompanied by
the presence of massive proteinuria. The outcome of the
control group of our study is in keeping with the natural
history of non-treated MGN patients: seven patients (30%)
showed a spontaneous remission, whereas other six patients
(26%) initiated a significant worsening of renal function
(50% SCr increase) during the study. All these latter patients
exhibited a massive proteinuria in parallel with the
appearance of renal function deterioration. By contrast, only
one patient in the treatment group showed progressive renal
insufficiency: a 79-year-old male with baseline moderate
renal insufficiency who persisted with massive proteinuria
after 6 months of tacrolimus treatment. Therefore, our results
show that the achievement of a complete or PR in MGN
patients by tacrolimus not only improve patient’s clinical
condition and avoid the complications of nephrotic syn-
drome, but also significantly reduce the risk for renal
function worsening. However, it should be emphasized that
long-term studies are necessary to confirm this beneficial
effect of tacrolimus on renal survival of MGN patients,
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Figure 6 | Mean doses and blood levels of tacrolimus.
Table 3 | Adverse events
Adverse event Control (n=23) Tacrolimus (n=25)
Glucose intolerance 2 4
Chest pain 2 0
Diarrhea 0 2
Gouty arthritis 0 1
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nephrotic syndrome relapsed after tacrolimus withdrawal and
that, although not statistically significant, control patients
tended to be older and to have more cases with eGFR lower
than 60 ml/min/1.73 m2 at baseline (Table 1).
In addition to massive proteinuria, male gender, older age,
and decreased renal function have been identified as
significant predictors of a poor outcome in MGN.14 We
found that baseline eGFR and treatment with tacrolimus
were the only factors statistically significantly correlated with
the achievement of a PR or CR. Whereas no patient over 50
years achieved spontaneous remisssion in the control group,
66% of treated patients over 50 years responded to
tacrolimus. Patients in the control group who deteriorated
renal function were older and had a lower baseline renal
function than the remaining control patients. Therefore, our
results are in agreement with the detrimental influence of age
and baseline renal function on the outcome of MGN, but also
indicate that patients combining the worse clinical predictor
factors (older age, male gender and moderately impaired
renal function) can achieve PR or CR after tacrolimus
treatment.
In a previous trial including MGN patients with preserved
renal function, cyclosporin (plus low-dose prednisone) was
given for 26 weeks and then tapering off over 4 weeks.12
Seventy-five percent of the treatment group had PR or CR,
but relapse of nephrotic proteinuria appeared in 43% of the
treated patients within the 22 weeks following cyclosporine
withdrawal. We designed a more prolonged period of
treatment (12 months) followed by a slowly tapering period
of other 6 months to investigate if this scheme could improve
the response of MGN to anticalcineurinic agents. We found,
however, that relapses appeared after complete tacrolimus
withdrawal in nine out of the 19 patients (47%) that were on
CR or PR by month 18, a relapse rate very similar to that
obtained with shorter courses of cyclosporin. Nevertheless, it
is important to remark that no relapses were observed
throughout the 6-month period of withdrawal, in spite of the
very low tacrolimus doses administered during this period
and the low blood levels of the drug, as shown in Figure 6.
This observation deserves to be emphasized, because it could
suggest that patients responsive to tacrolimus but showing
relapses after its complete withdrawal could be treated with
very low tacrolimus doses for longer periods to maintain a
sustained remission of the nephrotic syndrome. In fact, a
substantial number of treated patients in our study that
relapsed after tacrolimus withdrawal (and consequently were
retired from the study) were retreated in this way, achieving
again a remission. However, as in any long treatment with
anticalcineurinic drugs, even in very low doses, the risk of
nephrotoxicity remains a very important concern that should
be born in mind. No long-term studies have been performed
about the risk of nephrotoxicity by anticalcineurinics in
MGN.
A novelty of our study was the use of tacrolimus as
monotherapy. Although previous prospective trials have
found no benefits with steroid therapy alone in idiopathic
MGN,15 steroids in different doses and schedules are usually
co-administered in conjunction with other immunosuppres-
sive agents in most of prospective trial performed in
idiopathic MGN. Our study shows that steroid-free,
tacrolimus monotherapy induces very significant beneficial
effects in MGN. This point deserves mention because MGN
is the first cause of idiopathic nephrotic syndrome in aged
patients in whom side effects of steroids are particularly
common and severe.
Another strength of our study was the care about the
possible confounding effect of ACEI and ARB treatment.
Owing to the well-known antiproteinuric effect of these drugs
in patients with glomerular diseases, including MGN,16 we
included only patients with persistent nephrotic syndrome
after at least 2 months on ACEI/ARB treatment, and ACEI/
ARB doses were maintained without changes during the
study. The possible confounding influence of ACEI/ARB
treatment has been less carefully evaluated in previous studies.
Tacrolimus was well tolerated and no important side
effects were detected throughout the study. There were no
cases of acute renal function worsening, a potential serious
complication of tacrolimus-induced vasoconstriction in
patients with severe nephrotic syndrome. The low doses of
tacrolimus administered in our study, considerably lower than
those used for immunosuppression in solid organ transplan-
tation, can explain the absence of significant side effects.
Treatment of idiopathic MGN remains controversial. The
use of immunosuppresive therapies with high-dose steroids
and cytotoxics has demonstrated a conclusive efficacy, but the
number and severity of side effects, particularly among older
patients, is disturbing. As recently evaluated in a prospective
trial, synthetic adrenocorticotropin hormone can induce the
same beneficial effects than steroids and cyclophosphamide
in MGN.17 Rituximab, an anti-CD20 monoclonal antibody,
has also been shown to induce significant reduction in
proteinuria in an uncontrolled trial of MGN patients,18 but
prospective controlled trials are lacking. Similarly, some non-
controlled studies have reported a beneficial effect of
mycophenolate mofetil in MGN.19 As a general rule, however,
we think that an observation period including only
conservative therapies (diuretics and antihypertensives as
required, statins, ACEI, or ARB to decrease proteinuria) is
mandatory, taking into account the substantial number of
spontaneous remissions characteristic of this disease and that
are particularly common among those patients with favorable
prognostic factors (women, patients under 50 years). In
patients with persistent nephrotic proteinuria after such
observation period, as our study shows, monotherapy with
low-dose tacrolimus is a very useful and well-tolerated
therapeutic option, inducing remission in a great majority of
patients and significantly reducing the risk of renal function
worsening. Comparative studies between the different treat-
ments that have demonstrated a beneficial effect on MGN are
necessary to evaluate the benefits and drawbacks of these
therapeutic approaches. On the other hand, it would be
worthwhile to explore in future studies the introduction of
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non-nephrotoxic immunosuppressive therapies once
achieved remission by anticalcineurinics, to keep the patient
in remission after anticalcineurinic withdrawal.
MATERIALS AND METHODS
This study was a prospective, randomized, parallel, open-label, and
controlled trial conducted in 13 centers in Spain between January
2003 and September 2006. The study protocol was reviewed and
approved by each center’s Ethic Committee and written informed
consent was provided by all participants. The entry criteria were a
biopsy-proven MGN, age between 18 and 70 years, nephrotic-range
proteinuria (43.5 g/24 h) accompanied by hypoalbuminemia (ser-
um albumin o3 g/dl) during at least a 9-month period before
screening and an eGFR by Cockroft–Gault formula X50 ml/min/
1.73 m2. Included patients who also had to be treated with an ACEI
or an ARB at their maximal tolerated doses for at least 2 months
before screening. Exclusion criteria included the diagnosis of
diabetes mellitus, malignancy, systemic lupus erythematosus, or
any other systemic disease known to be associated with secondary
MGN, infections (including positive test for hepatitis C and B virus
and HIV) and patients treated with steroids or immunosuppressive
therapy within the 6-month period before screening.
Patients were randomized either to a control group or to a group
treated with tacrolimus (treatment group). Randomization was
performed by the clinical coordinating center using a table of
random numbers and was stratified by centers. Allocation conceal-
ment was performed by enclosing assignments in sequentially
numbered, opaque-closed envelopes. All the patients were instructed
to maintain the same doses of ACEI or ARB that they were taking at
randomization until the end of the study. Target BP was o130/
80 mm Hg in both groups; other antihypertensive drugs were
prescribed in addition of ACEI/ARB in those patients who did not
reach these target values. Target low-density lipoprotein cholesterol
was o160 mg/dl. Statin doses were increased, or treatment with
these drugs was initiated in patients who did not reach this low-
density lipoprotein cholesterol level in spite of dietary advice.
Patients randomized to the treatment group started tacrolimus at
a dose of 0.05 mg/kg/day, divided into two daily doses at 12-h
interval. Later doses were adjusted to achieve a whole blood 12-h
trough level between 3 and 5 ng/ml. When a remission was not
obtained after the first 2 months of treatment, doses were increased
to achieve levels between 5 and 8 ng/ml. Tacrolimus treatment was
continued for 12 months and then gradually tapered off for the next
6 months; a 25% tacrolimus dose reduction was indicated at months
12, 14, and 16 and treatment was withdrawn by month 18.
Follow-up visits were scheduled monthly during the first
4 months and thereafter every 2 months until month 18. In
addition, patients randomized to the treatment group were
controlled weekly during the first month, to adjust tacrolimus doses
by whole blood levels, to avoid acute renal function worsening and
to watch over any possible tacrolimus intolerance. At each visit, a
complete physical examination was performed, including BP. BP was
measured after 5 min of rest at a sitting position; the average of two
BP measurements was recorded. At each visit, blood was sampled for
standard hemogram, SCr, sodium, potassium, glucose, total
proteins, albumin, total cholesterol, and high-density lipoprotein
and low-density lipoprotein fractions, triglycerides, and trough
levels of tacrolimus. A 24-h urine collection was obtained at every
visit, and 24-h excretion of creatinine, protein, sodium, potassium,
and urea were measured; eGFR was calculated at every visit.
End points
The primary end point was the number of patients reaching CR or
PR. CR was defined as o0.5 g/24 h proteinuria plus stable renal
function (eGFR X50 ml/min/1.73 m2) and PR as proteinuria less
than 3.5 g/24 h and 50% lower than baseline proteinuria plus stable
renal function. Secondary end points were renal survival and the
evolution of proteinuria. Renal survival was estimated on the basis
of a 50% increase in baseline SCr concentrations. In control patients
showing a 50% SCr increase, functional factor such as an excessive
diuretic doses was carefully excluded before the definition of the end
point. In tacrolimus-treated patients, tacrolimus doses were reduced
by 25% every 2 weeks in the presence of a 50% SCr increase. If SCr
persisted 450% of baseline values 2–4 weeks after 475% reduction
of tacrolimus doses, definition of end point was established. Once
established the end point of a 50% increase in baseline SCr
concentrations, both in control and in treated groups, the patient
was retired from the study and treated according to the criteria of
each investigator.
Sample size
Assuming a rate of complete or partial response similar (in the range
of 75%) to that of the other anticalcineurinic drug, cyclosporine,
already tried in MGN,15 a rate of spontaneous response around
30%, with a type I error of 5%, a power of 80%, and a 10% of loss to
follow-up, we calculated that we needed about 24 patients per group
to detect the estimated differences.
Statistical analysis
Continuous data are reported as means7s.d. and/or 95% CI, as
appropriate. Categorical data are presented as absolute values and
percentages and analyzed by the w2 test or Fisher’s exact tests. For
both groups, changes from baseline (randomization) to 12 and 18
months in proteinuria, SCr, and eGFR were analyzed by means of an
analysis of covariance with factors for treatment, center, and baseline
value as a covariate. Differences between treatments were estimated
from the fitted model. Survival analysis was performed with
Kaplan–Meier curves and differences estimated by log-rank test. A
multivariable logistic-regression model, which included all the
potential confounding factors (i.e., age, gender, baseline SCr
concentration, eGFR, and proteinuria), was applied. A Po0.05
was considered to indicate statistical significance, and all analyses
were based on intention to treat (defined as all patients who took at
least one dose of medication and had efficacy data available after
randomisation). Calculations were computed with the aid of SPSS
software (version 13.0 for Windows).
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